Hanmi Pharmaceutical’s drug is designed to activate a receptor in skeletal muscle to both increase muscle mass and reduce fat. This engineered peptide gives Roche a clinical-stage asset that addresses a different target than the other obesity drugs in its pipeline.
The post Roche Gains Rights to Hanmi Obesity Drug That Reduces Fat, Preserves Muscle appeared first on MedCity News.
